NCT04892264View on ClinicalTrials.gov

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 3, 2021

Primary Completion Date

March 18, 2024

Study Completion Date

March 18, 2024

Conditions
Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Belantamab Mafodotin

Given IV

BIOLOGICAL

Daratumumab

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Lenalidomide

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Skeletal Survey X-Ray

Undergo X-ray skeletal survey

PROCEDURE

Low Dose Computed Tomography of the Whole Body

Undergo whole body low dose CT

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration and biopsy

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow aspiration and biopsy

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04892264 - Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | Biotech Hunter | Biotech Hunter